Form 4: Insider Reports SpyGlass Pharma Stock Conversions, IPO Purchase

A director and 10% owner of SpyGlass Pharma, Scott D. Sandell, reported the automatic conversion of preferred stock into common stock and a significant common stock purchase coinciding with the company's initial public offering.

Summary

• Scott D. Sandell, a Director and 10% Owner of SpyGlass Pharma, Inc. (SGP), filed a Form 4.
• The filing reports transactions occurring on February 9, 2026, coinciding with the closing of the Issuer's initial public offering (IPO).
• Various series of preferred stock (Series B, C-1, C-2, D, A, B) automatically converted into common stock on a one-for-one basis prior to the IPO.
• New Enterprise Associates 17, L.P. (NEA 17) converted 1,619,240 Series B, 1,370,168 Series C-1, 1,370,168 Series C-2, and 737,962 Series D Preferred Stock into an equivalent number of Common Stock shares.
• New Enterprise Associates 16, L.P. (NEA 16) converted 954,990 Series A and 402,273 Series B Preferred Stock into an equivalent number of Common Stock shares.
• NEA 17 also purchased 937,500 shares of Common Stock at a price of $16 per share.
• Following these transactions, NEA 17 beneficially owns 6,035,038 shares of Common Stock, and NEA 16 beneficially owns 1,357,263 shares of Common Stock.
• Mr. Sandell disclaims beneficial ownership for portions of the securities held by NEA 17 and NEA 16 in which he has no pecuniary interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates strong insider confidence with a significant purchase at the IPO price by a major investor, alongside the expected conversion of preferred shares, which is a normal part of going public.

Positives

• A significant purchase of 937,500 common shares at $16 per share by an entity associated with a director and 10% owner, indicating confidence in the company's valuation at its IPO price.
• The automatic conversion of preferred stock into common stock prior to the IPO simplifies the capital structure and is a standard step for companies going public.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance, as its purpose is to report insider transactions.

Management Comments

• The filing includes a disclaimer from Scott D. Sandell stating that he disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 17 and NEA 16 in which he has no pecuniary interest.

Industry Context

StockSavvy.ai notes that the conversion of preferred stock to common stock and subsequent insider purchases are typical events surrounding an Initial Public Offering (IPO) for a biotechnology or pharmaceutical company like SpyGlass Pharma. Venture capital firms like New Enterprise Associates (NEA) often convert their preferred holdings into common stock as part of the IPO process, and their continued investment or purchases at the IPO price can signal confidence to the market. This activity aligns with standard practices for early-stage investors transitioning to public market ownership.

Comparison to Industry Standards

• The automatic conversion of preferred stock to common stock prior to an IPO is a standard procedure for venture-backed companies, similar to recent IPOs such as Acelyrin (ACLY) or Kenvue (KVUE), where early investors' preferred shares converted to common stock upon listing.
• The purchase of common stock by an entity associated with a director and 10% owner at the IPO price of $16 per share is a strong signal of insider confidence, comparable to insider buying observed in other recent biotech IPOs where initial investors increased their stake post-listing, such as in the case of Third Harmonic Bio (THRD) or Structure Therapeutics (GPCR).

Related Party Transactions

• The transactions involve entities (NEA 17 and NEA 16) where the reporting person, Scott D. Sandell, serves as a manager of their general partners, indicating related party dealings in the context of the IPO.

Stakeholder Impact

• Shareholders: The IPO and insider purchase at the IPO price could instill confidence in new public shareholders regarding the company's valuation and future prospects.
• Employees: A successful IPO generally provides liquidity and potential wealth creation opportunities for employees holding stock options or restricted stock units.
• Investors (NEA 17, NEA 16): The conversion of preferred stock to common stock and the additional purchase solidify their investment in the public entity, allowing for future liquidity.

Next Steps

• The company has completed its initial public offering (IPO) on February 9, 2026, marking its transition to a publicly traded entity.

Key Dates

Recommendation

The filing reports standard insider transactions associated with an IPO, including preferred stock conversions and an insider purchase at the IPO price. While the insider purchase is a positive signal of confidence, a Form 4 primarily reports historical transactions and does not provide new operational or financial performance data. Therefore, a 'hold' recommendation is appropriate for existing investors to await further financial disclosures, and for potential investors to conduct deeper due diligence beyond this transactional report.

Keywords

SpyGlass Pharma, SGP, Form 4, Insider Trading, Stock Conversion, IPO, Preferred Stock, Common Stock, New Enterprise Associates, Scott D. Sandell, Beneficial Ownership